Chlorocresol Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a solution-grade 4-chloro-3-methylphenol intermediate intended for use as an antimicrobial preservative active substance in veterinary medicinal products. The material corresponds to CAS 59-50-7, EC 200-431-6, molecular formula C₇H₇ClO, and molar mass 142.58 g/mol. The designation “API grade” indicates manufacture under veterinary active substance GMP rather than classification as a therapeutic active in most formulations. The product is supplied under a manufacturer-specific article code and batch traceability identifier; no universal model number exists across suppliers. The solution concentration is expressed as percent weight/weight chlorocresol after dilution and is confirmed by HPLC against a certified reference standard. This material is not a final dosage form and is not administered without dilution or formulation-specific preservative efficacy validation. In dry solid dosage forms where water activity remains below 0.6, preservation is normally unnecessary; however, the solution is used in aqueous granulating fluids, film-coating dispersions, liquid-filled capsule matrices, oral solutions, premix intermediates, and multidose injectables when free water is present.

What release specifications govern a solution-grade chlorocresol intermediate?

Release specifications align with the Ph. Eur. chlorocresol monograph where the active substance is isolated, and with the solution-specific dossier. The solution form is released on declared content rather than on anhydrous solid content. Assay, related substances, pH, and microbial enumeration are routine markers. Residual solvents are controlled under ICH Q3C; elemental impurities are assessed under ICH Q3D. The vehicle must be declared on the certificate of analysis; aqueous systems, or water blended with propylene glycol or ethanol, are used where downstream compatibility permits. The following table summarizes representative solution-grade release attributes. The final acceptance limits are batch-specific and must be read from the certificate of analysis supplied with the product.

The solution should be warmed to 20–25 °C and mixed before sampling if stored below 10 °C, because crystallization can occur. Purified water should be used for dilution. Hard water with high calcium carbonate content can generate local precipitation and should be avoided unless the dossier specifically approves the water source.

If the Solution Is Added to Granulating Fluids or Film-Coating Dispersions

For tablets, capsules, powders, and granules, chlorocresol solution is introduced only when the manufacturing process creates a transient aqueous phase. High-shear wet granulation and aqueous film coating are the primary routes. The solution is diluted in the granulating fluid before addition to the high-shear mixer or fluid-bed granulator. Direct addition of concentrated phenolic solution onto dry powders can create localized concentration gradients, poor assay uniformity, and granule discoloration. The finished dry product should be controlled by a validated drying endpoint, typically loss-on-drying below 2.0% or water activity below 0.6, with residual chlorocresol confirmed by extraction and HPLC. For film-coated tablets, the coating dispersion is prepared with the diluted preservative solution and sampled before spraying to confirm absence of precipitate. During aqueous film coating, inlet air temperature and spray rate are set to maintain tablet bed temperature below 45 °C when chlorocresol is present, minimizing volatilization losses and preserving uniform film formation. Chlorocresol should not be combined with strong oxidizing agents in granulation fluids because the phenolic ring can degrade to colored quinone-like impurities.

In liquid-filled hard capsule matrices with water activity above 0.6, chlorocresol solution may be incorporated into the hydrophilic fill mass. Compatibility with gelatin shell plasticizers should be verified by capsule deformation testing and dissolution testing as referenced in Ph. Eur. 2.9.3 and the finished product dossier. Preservative efficacy in the filled capsule should be confirmed by challenge testing because the shell and fill matrix can sequester phenolic preservatives.

For multidose veterinary injectables, chlorocresol solution is typically applied at 0.05–0.2% w/v as chlorocresol. The exact concentration is selected by preservative efficacy testing according to Ph. Eur. 5.1.3 or USP <51>. Chlorocresol is active against Gram-positive bacteria and fungi, but activity against Pseudomonas aeruginosa may require challenge testing in the final formulation. The formulation pH should remain below 8.0 to maintain the undissociated phenolic species, which is the membrane-active form. The solution is added aseptically to the bulk product after heat sterilization or autoclaved only after a validated overage is established. Because chlorocresol is steam-volatile and can partition into elastomeric closures, fill-volume assay verification after terminal sterilization is required. Filling into bromobutyl or chlorobutyl elastomer-closed vials should be followed by stability-indicating assay for free chlorocresol over the proposed shelf life.

Comparative Preservative Performance in Multidose Veterinary Injectables

The following table summarizes formulation-relevant differences between chlorocresol and three common preservative systems. The values are drawn from pharmacopoeial use concentrations and compatibility reports. Published MIC data for specific veterinary field isolates is limited and should not replace preservative efficacy challenge testing in the target formulation.

Compared with benzalkonium chloride, chlorocresol is non-cationic and does not precipitate with anionic viscosity modifiers. Compared with thiomersal, chlorocresol is mercury-free, which simplifies waste disposal and avoids organomercurial sensitization concerns in some regions. Compared with phenoxyethanol, chlorocresol provides stronger antifungal activity at lower concentration but is more sensitive to pH values above 8.0. Chlorocresol differs from chloroxylenol, 4-chloro-3,5-dimethylphenol, by the absence of one methyl group; chlorocresol has higher water solubility and is more frequently referenced in pharmacopoeial injectable preservative contexts, whereas chloroxylenol is more often used in topical antiseptic products. The two phenolic preservatives are not interchangeable without formulation and challenge testing.

Managing Closure Sorption and Sterilization-Induced Concentration Shifts

Phenolic preservatives partition into elastomeric closures. Bromobutyl formulations generally show lower uptake than natural rubber, but no closure is non-absorptive. Free chlorocresol should be measured by HPLC in the finished vial after terminal sterilization and during stability storage. If the product is sterilized by moist heat at 121 °C for 15 min, loss to the headspace can occur; the headspace should be minimized, or the solution should be added through a pre-sterilized filter after the bulk has cooled. Filtration through 0.22 µm PVDF or PES membranes is recommended because these membrane types typically show low phenolic binding. Mixed cellulose ester membranes may adsorb phenolic compounds and reduce assay recovery. The filtration setup should be flushed with a small volume of filtered vehicle before product collection to minimize filter-surface loss.

Stability-indicating methods should quantify both free chlorocresol and total chlorocresol after extraction. A reverse-phase HPLC method using a C18 column, phosphate-buffered water-acetonitrile mobile phase at pH 3.0, and UV detection at 280 nm is suitable for many veterinary dosage forms when validated for specificity, linearity, accuracy, and precision under ICH Q2(R1). Method validation should include forced degradation under heat, light, and oxidative conditions to confirm resolution of degradation products from the chlorocresol peak.

For premix and oral solution applications, the preservative solution is diluted into the aqueous phase before mixing with liquid feeds or drinking water. In liquid feed systems, the final pH should be validated because chlorocresol activity declines above pH 8.0. In medicated premix powders intended for reconstitution in liquid feed, the solution is not added directly to dry carrier; it is incorporated into the aqueous phase before blending. Mixing homogeneity is confirmed by sampling from a ribbon blender or ploughshare mixer after a validated mixing time, with assay of chlorocresol at top, middle, and bottom sampling ports. Solutions for oral administration should be protected from light because chlorocresol can form colored photodegradation products. Amber glass or opaque HDPE containers stored at 15–25 °C are typical for light-sensitive aqueous formulations.

Chlorocresol solution should be handled in closed transfer systems or with local exhaust ventilation. The phenolic compound is a skin and eye irritant and can cause contact dermatitis. Nitrile gloves and chemical goggles are appropriate personal protective equipment; natural rubber gloves should not be used because phenolic permeability may be higher. Spills should be collected with inert absorbent and not mixed with strong oxidizers. Storage below 10 °C can produce crystallization; the container should be warmed to 20–25 °C and mixed before use. Prolonged heating above 40 °C should be avoided to reduce volatilization and oxidative discoloration. The solution is not intended for direct animal administration without a validated formulation, preservative efficacy test, and batch release through a finished dosage manufacturing process.

Regulatory File Anchors for Veterinary Active Substance and Finished Product

Veterinary medicinal products incorporating chlorocresol solution are released under the approved marketing authorization dossier. In the European Union, finished product quality and safety are assessed within the framework of Directive 2001/82/EC; manufacturing must comply with GMP obligations under Commission Directive 91/412/EEC. Preservative efficacy data are required for multidose formulations and are assessed using Ph. Eur. 5.1.3 or USP <51> challenge organisms, including Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 9027, Candida albicans ATCC 10231, and Aspergillus brasiliensis ATCC 16404. Residual solvent and elemental impurity documentation should reference ICH Q3C and ICH Q3D expectations where the dossier applies them to the solution-form active substance.

The batch documentation supplied with the product includes the certificate of analysis, a safety data sheet compliant with CLP, and where applicable, a valid CEP or TSE/BSE statement. The finished dosage manufacturer retains responsibility for final product clearance, preservative efficacy, leachable evaluation, and stability under the registered container-closure system. Single-dose veterinary parenterals should not contain preservatives unless justified by the marketing authorization; chlorocresol solution in single-dose products may be unnecessary and can contribute to injection site reactions. For multidose presentations, the minimum effective concentration should be selected by challenge testing rather than by reference to a fixed compendial concentration.